Current taxane formulations and emerging cabazitaxel delivery systems

被引：0
作者：
Boyang Sun
Robert M. Straubinger
Jonathan F. Lovell
机构：
[1] State University of New York,Department of Biomedical Engineering, University at Buffalo
[2] State University of New York,Department of Chemical and Biological Engineering, University at Buffalo
[3] State University of New York,Department of Pharmaceutical Sciences, University at Buffalo
来源：
Nano Research | 2018年 / 11卷
关键词：
cabazitaxel; Jevtana; taxanes; drug delivery systems; nanocarriers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is approved for treating hormone-refractory metastatic prostate cancer previously treated with docetaxel. Although first-generation taxanes (i.e. paclitaxel and docetaxel) have sparked broad interest in a variety of drug delivery vehicles, fewer have yet been developed for cabazitaxel. This review summarizes several clinical-stage approaches for taxane formulation and recent efforts to develop novel cabazitaxel delivery systems.
引用
收藏
页码：5193 / 5218
页数：25
相关论文
共 1017 条
  • [1] Crown J.(2000)The taxanes: An update Lancet 355 1176-1178
  • [2] O’Leary M.(2012)Update on taxane development: New analogs and new formulations Drug Des. Devel. Ther. 6 371-384
  • [3] Yared J. A.(2012)Docetaxel nanotechnology in anticancer therapy ChemMedChem 7 952-972
  • [4] Tkaczuk K. H. R.(2013)Paclitaxel drug delivery systems Expert Opin. Drug Deliv. 10 325-340
  • [5] Zhao P. X.(2011)Cabazitaxel: A novel secondline treatment for metastatic castration–resistant prostate cancer Drug Des. Devel. Ther. 5 117-124
  • [6] Astruc D.(1983)Cell surface P–glycoprotein associated with multidrug resistance in mammalian cell lines Science 221 1285-1288
  • [7] Zhang Z. P.(2013)Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane–resistant tumors Clin. Cancer Res. 19 2973-2983
  • [8] Mei L.(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration–resistant prostate cancer progressing after docetaxel treatment: A randomised open–label trial Lancet 376 1147-1154
  • [9] Feng S. S.(1998)Paclitaxel (Taxol®): A success story with valuable lessons for natural product drug discovery and development Med. Res. Rev. 18 315-331
  • [10] Paller C. J.(2004)A tale of two tumor targets: Topoisomerase I and tubulin The Wall and Wani contribution to cancer chemotherapy. J. Nat. Prod. 67 232-244
12345678910